Literature DB >> 3937287

The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits.

G Agnelli, M R Buchanan, F Fernandez, J Hirsh.   

Abstract

Tissue type plasminogen activator (t-PA) is an effective thrombolytic agent in experimental animals and in humans. We have previously observed that the thrombolytic effect of t-PA persists beyond its time of clearance from the circulation and that wound bleeding induced by a high dose infusion of t-PA is delayed for at least one and a half hours after commencing the infusion. These observations suggest that improved thrombolysis may be obtained with t-PA by infusing a high dose over a short period of time. To test this hypothesis we compared the thrombolytic and hemorrhagic effects of t-PA infused over 240, 60, 30 and 15 minutes in the rabbit. A 4 hour infusion of 30,000 U/kg of t-PA produced 36% thrombolysis. The same dose of t-PA infused over 60, 30 and 15 minutes produced 87%, 88% and 96% thrombolysis, respectively (p less than 0.01). The 1 hour infusion of 30,000 U/kg of t-PA produced a significant increase in blood loss relative to saline infusion (p less than 0.01). The same dose infused over 30 and 15 minutes did not produce significantly more bleeding than saline. A higher dose of t-PA, 60,000 U/kg, infused over 4 hours, produced 95% thrombolysis, but was associated with a significant increase of blood loss (p less than 0.001). Our findings suggest that improved thrombolysis with t-PA with minimal bleeding side-effects is achieved in rabbits when t-PA is administered in a relatively high dose given over a short period of time.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3937287     DOI: 10.1016/0049-3848(85)90314-7

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  7 in total

1.  Novel and Innovative Dosing Regimens in Thrombolytic Therapy for Acute Myocardial Infarction.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Achieving Optimal Reperfusion without Adjunctive Antithrombotic Therapy: Novel Thrombolytic Dosing Strategies.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 3.  Use of plasminogen activators in venous thrombosis.

Authors:  J Hirsh; A G Turpie
Journal:  World J Surg       Date:  1990 Sep-Oct       Impact factor: 3.352

4.  Coronary Artery Patency and Survival in Clinical Trials.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 5.  Thrombolytic therapy in the elderly. Pharmacoeconomic considerations.

Authors:  K Ramanathan; C J Ellis; H D White
Journal:  Drugs Aging       Date:  1996-04       Impact factor: 3.923

Review 6.  Pharmacokinetic optimisation of the treatment of deep vein thrombosis.

Authors:  A Iorio; G Agnelli
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

7.  The effects of recombinant tissue-type plasminogen activator (rt-PA) on canine cadaver lung transplantation.

Authors:  S Akasaka; H Nishi; M Aoe; H Date; A Andou; N Shimizu
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.